ITEMS IN AFP WITH KEYWORD:
Dapagliflozin will lower A1C levels by an average of 0.7 percentage points when used alone or by an average of 0.5 percentage points when added to metformin therapy. Its effect on diabetes-associated morbidity and mortality has not been studied, and although it is well tolerated, there is an associa...
This statement from American and European diabetes societies suggests that tighter control of hyperglycemia be attempted only in patients with a recent diagnosis and a low risk of hypoglycemia; who have a long life expectancy with few or no comorbidities, including cardiovascular disease; and who ar...
Jun 1, 2015 Issue
Tight Glycemic Control for Type 2 Diabetes Mellitus (Over Five Years) [Medicine by the Numbers]
Studies show that none were helped and 1 in 6 patients were harmed. See why.
n this retrospective analysis, which benefits from large numbers of patients but suffers from possible biases, patients who initially took an oral hypoglycemic other than metformin (Glucophage) were significantly more likely to require a second oral agent.
Bariatric surgery in conjunction with intensive medical therapy results in significantly enhanced glycemic control at three years compared with medical therapy alone, as well as better weight control, less use of glucose-lowering medications, and improved quality of life.
For too long, the debate in diabetes has centered on the question: Is this medication harmful? It's time to revisit the more fundamental question: Is this treatment beneficial?
In patients with diabetes, ACE inhibitors decrease cardiovascular events and all-cause mortality. ARBs do not. Both drug classes decrease heart failure incidence. Although both drug classes have been available for almost 15 years, there is only one study of 250 patients that directly compared their ...
May 15, 2014 Issue
Glycemic Control in Type 2 Diabetes (Drug Treatments) [Clinical Evidence Handbook]
What are the effects of blood glucose–lowering medications in adults with type 2 diabetes?
A new approach to the care of adults with type 2 diabetes emphasizes proven interventions that improve duration and quality of life.
Over five years, treatment with metformin for three years, with other hypoglycemics as needed, reduced the likelihood of death, nonfatal stroke, or the need for vascularization compared with treatment beginning with glipizide (Glucotrol). Cardiovascular events were not individually reduced with metformin compared with glipizide.